PLXS - NASDAQ

Good morning, and welcome to the Plexus Corp. conference call regarding its fiscal first quarter 2023 earnings announcement. My name is Liz, and I will be your operator for today's call. [Operator Instructions]. I would now like to turn the call over to Mr. Shawn Harrison, Plexus’ Vice President of Communications and Investor Relations. Shawn?

Thank you, Liz. Good morning, everyone, and thank you for joining us today. Some of the statements made and information provided during our call today will be forward-looking statements, including, without limitation, those regarding revenue, gross margin, selling and administrative expense, operating margin, other income and expense, taxes, cash cycle, capital allocation and future business outlook. Forward-looking statements are not guarantees, since there are inherent difficulties in predicting future results, and actual results could differ materially from those expressed or implied in the forward-looking statements. For a list of factors that could cause actual results to differ materially from those discussed, please refer to the company's periodic SEC filings, particularly the risk factors in our Form 10-K filing for the fiscal year ended October 1, 2022, and the Safe Harbor and fair disclosure statement in yesterday's press release. We encourage participants on the call this morning to access the live webcast and supporting materials at Plexus' website, www.plexus.com, clicking on Investors at the top of that page. Joining me today are Todd Kelsey, Chief Executive Officer; Steve Frisch, President and Chief Strategy Officer; Pat Jermain, Executive Vice President and Chief Financial Officer; and Oliver Mihm, Executive Vice President and Chief Operating Officer. Consistent with prior earnings calls, Todd will provide summary comments before turning the call over to Steve and Pat for further details. Let me now turn the call over to Todd Kelsey. Todd?

Thank you, Shawn. Good morning, everyone. Please advance to Slide 3. Our fiscal 2023 started strong, as we capitalized on the momentum built during fiscal 2022. As I reflect on the market conditions and supply chain dynamics of 12 months ago, I'm quite pleased with our performance in the fiscal first quarter. Amid unexpected demand volatility, we met our guidance and delivered 34% year-over-year revenue growth, generated an industry-leading GAAP operating margin, and nearly doubled our GAAP earnings per share year-over-year. We also advanced our efforts to be an ESG leader, an endeavor that our customers are taking notice. Our fiscal first quarter revenue of $1.09 billion, reflected strong demand from many customers, even as we experienced unexpected volatility from others. Semiconductor capital equipment demand was lower than our customers anticipated 90 days ago due to weakness in the memory market, paired with the effects from the US export control order. In addition, we experienced new program ramp schedule changes, a dynamic that is expected to be resolved as we move through fiscal 2023. Finally, we continued to have unfulfilled demand by more than $100 million, given ongoing supply chain challenges associated with lagging edge semiconductors. I would note that our average semiconductor lead time declined only 4% from last quarter, and remains in excess of 300 days. We delivered GAAP operating margin of 5.2%, inclusive of stock-based compensation expense and the cost associated with the ramp up business at our new facility in Bangkok, Thailand. With strong customer interest, we continue to anticipate our operations in Bangkok will be profitable exiting this fiscal year. Finally, we delivered GAAP EPS of $1.49, which included $0.21 of stock-based compensation expense. We won 29 new manufacturing programs during the quarter worth $158 million, including several programs associated with secular growth markets. As we discussed in recent quarters, supply chain conditions continue to slow the decision-making process for some customers that we anticipate will partner with Plexus. However, we see this trend reversing during our fiscal second quarter, driving increased wins for the remainder of the fiscal year. Our funnel of qualified manufacturing opportunities expanded nearly $250 million sequentially to a record $3.6 billion, reflecting the delayed decision-making and significant potential to increase our wins. Please advance the Slide 4. We continued to demonstrate our commitment to be a leader in environmental, social, and governance, through how we innovate and operate. Late last year, we joined the Semiconductor Climate Consortium as a founding member, partnering with many of our SemiCap customers and industry-leading technology firms that are focused on accelerating the reduction of greenhouse gas emissions throughout the semiconductor value stream. In addition, we received ASM International's PRISM Award For Supply Chain Sustainability Innovation. The award was given as a result of our global internal competition called BEST, which fosters team member innovation and continuous improvement. This competition has highlighted ESG initiatives such as smart metering, water usage reduction, and implementation of alternative energy sources, all of which are helping to reduce our environmental impact. We are proud that our efforts were recognized by an important customer and SemiCap industry leader. Please advance to Slide 5. We are guiding fiscal second quarter revenue of $1.02 billion to $1.07 billion, GAAP operating margin of 4.5% to 5%, inclusive of approximately 60 basis points of stock-based compensation expense, and GAAP EPS of $1.06 to $1.24, inclusive of $0.21 of stock-based compensation expense. Our guidance reflects the continuing impact of the near-term demand dynamics that affected our fiscal first quarter, including weakness in SemiCap demand, a near-term slowdown in certain new program ramps, and well in excess of $100 million of unfulfilled customer demand. Our operating margin guidance reflects reduced fixed and administrative cost leverage, coupled with our typical seasonal cost increases associated with merit-based salary adjustments, and US payroll tax resets. We expect to overcome both as we move through fiscal 2023. Finally, our fiscal second quarter EPS guide is impacted by higher interest expense and tax expense compared to our fiscal first quarter. I continue to see the potential for strong performance in fiscal 2023 and beyond. While recognizing macroeconomic and geopolitical uncertainties, we have the opportunity to deliver industry-leading profitability and revenue growth rates significantly in excess of the markets we serve. We expect to return to quarterly sequential revenue growth beginning in our fiscal second half associated with robust Healthcare/Life Sciences and Aerospace and Defense market sector demand, normalizing existing program ramp schedules, additional new program ramps as we benefit from share gains, and participation in secular growth markets, and continued backlog conversion, given our focus on resolving supply chain challenges. In looking at our end markets for fiscal 2023, our Healthcare/Life Sciences market sector is poised to have a tremendous year. The sector is benefiting from a sustained recovery and demand for elective procedures, numerous new program ramps that have yet to reach steady state, and our continued efforts to mitigate supply chain challenges. We see the opportunity for healthy growth from our Industrial sector due to our participation in secular growth markets such as warehouse and factory automation, our continued efforts to clear supply chain challenges, and new program ramps in developing markets such as electrification. While supply chain demand - or while SemiCap demand is much weaker than 90 days ago, we continue to anticipate we'll outperform the market, given share gains and new program ramps. Finally, demand from our Aerospace and Defense market sector continues to recover, particularly in commercial aerospace. Supply has been the gating factor for several quarters now, but our progress in resolving those challenges, provides the potential for sequential revenue growth throughout the remainder of fiscal 2023, resulting in robust sector growth for the fiscal year. With the anticipated return of sequential revenue growth for our fiscal second half, we are focused on achieving our 5.5% GAAP operating margin goal exiting the fiscal year. I will now turn the call over to Steve for additional analysis of the performance of our market sectors and operations. Steve?

Thank you, Todd. Good morning. I will start on Slide 6, with a review of the fiscal first quarter performance of our market sectors, as well as our expectations for the sectors for the fiscal second quarter of 2023. Starting with the Industrial sector, revenue declined by 9% in the fiscal first quarter. The result was lower than our expectation of a mid-single-digit decline. Although we anticipated forecast reductions from our SemiCap customers as we started the fiscal first quarter, almost all of the SemiCap customers’ adjusted demand lowered during the quarter due to softening end markets and the impact of the recent export control order from the US Department of Commerce. For the fiscal second quarter, the export control order and the softness in the memory market, is pressuring demand in the SemiCap sub-sector. As a result, we are forecasting approximately a 10% decline in the Industrial sector for the fiscal second quarter. As we look to the second half of fiscal 2023, we expect sequential growth in the Industrial sector, as new program ramps within the sector start to materialize. On top of the exceptional growth of 17% in the fiscal fourth quarter of 2022, our Healthcare/Life Sciences sector grew an additional 4% in the fiscal first quarter. The result was in line with our expectation of a mid-single-digit increase. Contributions from new program ramps supported the growth. As we start the fiscal second quarter, we are working with our customers to implement engineering changes on active program ramps. The short-term impact is that we expect our Healthcare/Life Sciences revenue to be flat for the fiscal second quarter, before the sector returns to healthy sequential growth in the fiscal third quarter. Our Aerospace and Defense sector declined 2% in the fiscal first quarter. The result was in line with our expectations of a low single-digit decrease. Improved shipments for several customers could not offset the revenue headwinds from the end of life program we highlighted last quarter. Although fulfillment of our customers’ overall demand is still hampered by supply chain constraints, our procurement team has made meaningful progress. As such, we anticipate a low single-digit increase in the Aerospace and Defense sector for the fiscal second quarter. We believe our ability to fulfill demand will continue to improve throughout fiscal 2023. Please advance the Slide 7 for an overview of our wins performance. We won 29 new manufacturing programs during the fiscal first quarter that we expect to generate $158 million in annualized revenue when fully ramped into production. Although the result was below our expectation, we believe that near-term macroeconomic and geopolitical uncertainties are extending decision-making cycles. We highlighted this view in our previous earnings calls, and as we exit the fiscal first quarter, our funnel of qualified opportunities illustrates this dynamic. As shown on Slide 8, our robust funnel of qualified manufacturing opportunities jumped by nearly $250 million to $3.6 billion in the fiscal first quarter, easily surpassing the record levels of fiscal 2023. As we look at the metrics within the funnel, our program win rates continue to be high, and cancellations of programs within the funnel remain normal. Based upon current visibility into the funnel, we anticipate a noticeable rebound in our new program wins in the fiscal second quarter. Going back to the fiscal first quarter manufacturing wins, Slide 9 has a few sector and region highlights. The wins were spread across the sectors. Our Industrial sector won 14 new programs, including two new logos valued at $74 million. Our Healthcare/Life Sciences sector won nine new programs, including one new logo valued at $61 million. And our Aerospace and Defense sector won $23 million in new programs. Wins for the EMEA region were exceptionally strong for the third quarter in a row. With the additional $93 million in wins in the fiscal first quarter, the region is poised for significant growth. I'll provide insight into some of their recent wins next. Please advance to Slide 10 for highlights of the fiscal first quarter wins. I'll start with two significant wins from our Industrial sector. The first product is used in factory automation and process control. We expect to start ramping this program from a new logo into our Oradea, Romania facility by the end of this fiscal year. The second Industrial sector win is a next-generation 3D printer from a current customer. This new additive manufacturing system will join the family of products already manufactured by our team in Appleton, Wisconsin. Our Healthcare/Life Sciences team expanded our market share with a customer who produces infusion pumps. This takeaway from a competitor was a direct result of our Oradea manufacturing team's exceptional performance for this customer during the pandemic. The Healthcare/Life Sciences team also won an ultrasound system used for cardiac care. This product will also be produced by our team in Oradea, Romania. Finally, our Aerospace and Defense wins include the brake controller for commercial aircraft. This program will be added to the platform of products we build for this customer in Neenah, Wisconsin. Next, I would like to turn to operating performance on Slide 11. During our fiscal first quarter, our team experienced demand volatility in SemiCap customer forecast, continued challenges in securing supply of lagging edge semiconductors, and engineering changes within process new program ramps. In spite of these challenges, they delivered strong GAAP operating margin performance of 5.2%. These challenges, combined with seasonal impacts, are putting short-term pressure on operating margin in the fiscal second quarter. As we look beyond the current quarter, we see the potential for fiscal 2023 revenue growth that exceeds our 9% to 12% annual target. With an unfulfilled backlog of more than $100 million, stabilizing customer forecasts, new program ramps, and continued action to improve supply constraints, the team is focused on delivering the revenue potential, while achieving 5.5% GAAP operating margin as we exit fiscal 2023. I will now turn the call to Pat for an in-depth review of our financial performance. Pat?

Thank you, Steve, and good morning, everyone. Our fiscal first quarter results are summarized on Slide 12. Gross margin of 9.3% was at the midpoint of our guidance and slightly below last quarter, due to ongoing investments and fixed costs, including our new Thailand facility. Selling and administrative expense of $44 million was favorable to guidance, primarily due to lower incentive compensation expense. As a percentage of revenue, SG&A was 4%, which was consistent with expectations. GAAP operating margin of 5.2% was also at the midpoint of our guidance, and included 53 basis points of stock-based compensation expense. Non-operating expenses were favorable to expectations as a result of additional interest income and lower factoring fees due to a near-term reduction in receivables factored. GAAP diluted EPS of $1.49, met the midpoint of our guidance for the reasons previously mentioned. Turning to our cash flow and balance sheet on Slide 13, as anticipated, for the fiscal first quarter, we made investments in working capital to align with our customers’ demand. Cash investments in operations totaled $49 million, while capital expenditures totaled $23 million. During the quarter, we purchased approximately 116,000 shares of our stock for $11.5 million at an average price of $99.12 per share. We have approximately $35 million available under the current $50 million authorization, and expect to execute repurchases on a consistent basis throughout fiscal 2023. With a strong and liquid balance sheet, investments in operations and our share repurchase program, were funded through a combination of cash and borrowing under our revolving credit facility. Our quarter end balance sheet included cash of $248 million and debt of $516 million. At the end of the quarter, we had $180 million available to borrow under our credit facility. For our fiscal first quarter, we delivered return on invested capital of 13.8%, which was 480 basis points above our weighted average cost of capital. Strong operating performance this quarter, compared to the prior year fiscal first quarter, led to an improvement in ROIC of 380 basis points. During the fiscal first quarter, we experienced an increase in working capital requirements, which led to cash cycle days above expectations and sequentially higher by six days. Please turn to Slide 14 for more details on our cash cycle. Sequentially, gross inventory dollars increased by less than 3%, while inventory days increased by seven. The increase in days resulted from strategic investments to support new program ramps and the impact on inventory from demand volatility within the quarter. Partially offsetting the increase in inventory days was a four-day increase in customer deposit days. We now have over 30% of our gross inventory covered with cash deposits. This compares to less than 15% four years ago. Accounts payable days sequentially reduced by three days related to earlier procurement of inventory and customer demand fluctuations. As Todd has already provided the revenue and EPS guidance for the fiscal second quarter, I'll review some additional details, which are summarized on Slide 15. Fiscal second quarter gross margin is expected to be in the range of 8.8% to 9.2%. At the midpoint, gross margin would be approximately 30 basis points lower than the fiscal first quarter. Seasonal compensation cost increases, as well as the reset of payroll taxes for US employees, will negatively impact gross margin by approximately 50 basis points. We expect selling and administrative expenses in the range of $44.5 million to $45.5 million, sequentially higher primarily due to the seasonal compensation headwinds, which total about $1 million. Non-operating expenses are expected to be in the range of $10.2 million to $10.7 million, sequentially higher, primarily due to increased borrowing under our revolving credit facility, along with the impact of rising interest rates. Our tax rate for the fiscal second quarter is expected to be in the range of 15% to 17%, while the full year tax rate is projected at 14$ to 16%. Our expectation for the balance sheet is that working capital investments will modestly increase compared to the fiscal first quarter. Based on our revenue forecast, which has been impacted by near-term demand volatility, we expect cash cycle days in the range of 110 to 115 days. With modest working capital investments, coupled with capital expenditures to support anticipated fiscal 2023 revenue growth, we expect breakeven to a slight usage of cash for the fiscal second quarter. A few comments on the full year. We continue to expect capital spending in the range of $110 million to $130 million, and plan for free cash flow to improve as we move through fiscal 2023, targeting to end the year with close to $50 million of free cash flow. With that, Liz, let's now open the call for questions.

[Operator Instructions]. Our first question comes from Jim Ricchiuti with Needham. Your line is now open.

Hi. Good morning. I was hoping to get some additional color on the schedule changes you alluded to with some of these program ramps. And you may have elaborated that. I may have just missed it, but I wonder if you could talk in terms of the market verticals where you're seeing this, and whether this is something that you see as company-specific, or potentially just a reflection of the more uncertain macro environment. Thank you.

Yes, Jim, so this is Todd. I’ll start out with this question, but if we think about program ramps in general, it's common for them to be a bit lumpy in the way that they progress over time. And if you recall back to a year ago when we started to talk about this small number of very large program ramps that we had underway, we talked about it, or I talked about it being in the range of $25 million to $50 million of sequential growth per quarter. And the reason for that range, part of it is because you can expect that there could be changes to the product as you go through this. So, and if you recall our results, we ended up overshooting the high end on this, so they were progressing extremely well, and now it’s paused, I would call it just a bit, not that the ramps have stopped. They've just slowed a bit as a result of some changes that need to be made on the engineering front within the program. So, nothing out of the ordinary, other than perhaps it happened a bit later than we had anticipated when we were looking at this, but the programs still have a great potential and will continue to ramp aggressively and I'd expect as we - we'll be moving ahead, at least on a good portion of that through our fiscal second quarter as we exit it, and then through the remainder of fiscal 2023.

Is there a way to think about this in terms of the number of programs? I'm curious how spread out this is among different customers or different ramps, specific.

It's a small number of significant programs. So, that's the reason for the impact. So, I'd call it - it's not market dynamics. It’s essentially product dynamics that we have right now, and you can see that at least - from Steve's commentary, that at least some of it impacts our healthcare sector, and that's why it's flat this quarter rather than continued sequential growth because they're on a tear right now.

Okay. And one final question, and I'll jump back in the queue. I'm not sure how to - what to make of what you're seeing in terms of supply chain. It sounds like it's getting a little better, but it's still, yes, pretty significant headwind for you. As you think about the sequential improvement that you're anticipating in this second half, what are some of the assumptions that you're making with respect to some of the supply chain challenges?

Yes, I would say that we're assuming it stays about the same. So, one of the things, though, that we'd anticipate is within Aerospace and Defense, we'd continue to clear more supply challenges in aerospace, because it's getting - if you recall, our other demand from our other sectors, it ramped faster, the demand curve. So, we were able to clear a significant amount of that demand in the late fiscal 2022 timeframe. Aerospace and Defense was about a half a year to three quarters of a year behind in the demand increasing. So, we're getting to the point where we expect we'll be able to be clear in some of those challenges, but we don't expect the supply chain to change meaningfully.

Got it. Thank you. I'll jump back in the queue.

Our next question comes from David Williams with The Benchmark Company. Your line is now open.

Hey, good morning. I think she said David. I think she said my name. She cut out there. So, thanks for taking the question. And maybe, Todd, first, previously I think you guys have talked about on the SemiCap equipment business, you expected maybe a 10% drop would be kind of reflect a 2% headwind to the overall revenue base. Do you think that what you're seeing now in that SemiCap equipment is significant, and do you think it rebounds? And then, of course, in the past, I think you've had less exposure on the logic side. So, just kind of curious maybe any of the dynamics around that and any other color you could provide.

Yes, I'll start with some of this, David, and then I'll pass it off to Steve for additional color. Last quarter, we talked about kind of a worst case scenario for SemiCap. We thought it - our SemiCap could be down 10%. It’s close to that range, but I call it in the single-digits down is what we're modeling right now. So, I think we've captured it pretty well. We still believe that 10% number is about right, and that would have about a 2% ballpark impact to our revenue expectations. Now, granted, they're still quite strong. So, I would say the 2% is on the - I don't want to call it negligible, but it's not a significant portion of the growth we're expecting.

And maybe just to add on to that, there's the existing products that we have. We've also been successful in winning new programs. And so, we have, and we do expect some new program ramps with SemiCap in fiscal ’23, which will offset some of the softness with the current demand. So, from our perspective, we're still expecting sequential growth in this area as we go through ‘23.

Yes. And I would say we're cognizant that the experts are projecting anywhere from high teens to 25% down in the SemiCap equipment space. So, we're conscious of that, and that is reflected in our forecast.

Okay. All right, fantastic. Thank you. And then maybe just on the Aerospace and Defense demand, it seems to be strengthening just kind of from what you've talked about, but the funnel trunk sequentially and the revenue was down sequentially. Do you see - is this more new program ramps that are coming in, improving demand maybe around the periphery, or maybe it's just a signpost that you're reading that looks like the demand is set to improve?

Yes. So, I mean, just to be clear on demand, demand has been exceptionally strong through ’22, and even as we go into ’23. It’s really - we've really seen it come back from a demand standpoint for several quarters. It's really more associated working with our customers as it has come back to get the supply pipeline correctly. And so, our challenge has really been getting work with our customers to get the pipeline of materials flowing to meet that demand. And so, we're starting to see some of those efforts of fiscal ‘22 starting to pay off in terms of getting the right quantity and types of materials pipeline. And so, that's why we believe we're making a bit of a turn on the growth in Aerospace and Defense, as opposed to what we saw as we went through the back half of ‘22.

Okay, very helpful. And maybe just one last one here is just kind of thinking about the $100 million of unfulfilled demand. It's been rolled forwards for several quarters here. I'm thinking that's just more related to the supply dynamics, but does the guidance factor in maybe fulfilling any of that or capturing that demand, or do you expect that to continue to roll forward for a few more quarters?

Yes, at this time, it continues - I would say it continues to roll forward, but what I would highlight is that's a different $100 million every quarter. So, we continue to fulfill other demand, but there's new unfulfilled demand that creeps in as well. But I expect that'll continue as we progress through ‘23.

All right, very good. Thanks again and congrats on the solid execution here.

Our next question comes from Matt Sheerin with Stifel. Your line is now open.

Yes, thanks. Good morning. I wanted to ask about the commentary from Steve regarding the wins, which were, I think, below expectations. And Steve, you talked about customers extending their decision-making on, I guess, new programs. Is there anything unique or common in terms of reasons that you're hearing from customers, whether or not they're pushing out new product introductions, or delaying a decision-making in terms of moving from one region to the other? Anything common about what you're hearing there?

I wouldn't say there's common across the sectors, but as it relates to what we're seeing in the individual sectors, in Aerospace and Defense, we talked about the fact that they have this pent-up backlog and everybody's been focusing on supply chain and making sure that they can deliver the orders that they have today versus moving product from potentially one supplier to the next or even changing their outsourcing strategy. So, in Aerospace and Defense, I think it’s just a matter of them catching up with the demand that they have. And we saw that four to six quarters ago, that was a similar phenomena that we saw in some of the other sectors. As we look at like Healthcare/Life Sciences, I would say now with the kind of the demand returning for them, them looking at the macroeconomic uncertainties, we are seeing and having more conversations associated with changes in supply strategy. And specifically, we have a few customers we're talking to about, are they going to shift their strategy from doing it internally to outsourcing their manufacturing? We see a few larger opportunities like that starting to pop up. And then in industrial, again, I think it goes - it’s mixed across the sub-sectors. In semiconductor capital equipment, the whole issues associated with the geopolitical environment in China, is causing several of those suppliers to look at their sourcing strategies, and we have benefited from companies that want to exit that market and move into some of our southeast Asia locations. And so, I wouldn't say there's a common theme. It’s really a bit of a mix, but I think the supply chain constraints and the macroeconomic uncertainties is causing everybody to think just a little bit differently.

There was a bit of pause around the holidays as well too. I suspect it had a bit to do with that. And we're off to a good start in Q2. So, we're seeing some signs that there was a bit of pent-up demand and delayed decision-making around those holidays.

Okay. Thank you for that. And then I wanted to just ask about the inventory and the working capital and the cash flows, which have also been, in terms of free cash flow, obviously below where you could be. And I know Pat, you're expecting net inventory days or inventory or cycle days to be up again, up significantly year-over-year, despite the cash deposits being up. So, how should we think about that inventory position as we get through the rest of the year, given that you look like you're looking at sequential growth in the back half. And then what could we think about free cash flows as we get through the year?

Yes, okay. So, I'll start by saying, I think we're starting to level off our inventory, Matt. If you look at the increase from year-end to Q1, we were up $42 million in inventory. Really good to see cash deposits up $31 million, so almost a full offset. Q2 could see increase of $25 million to $50 million in inventory to support new program ramps. I think the back half, as we see more sequential revenue growth, is an opportunity to bring down our days. And let me step back and just - we ended fiscal 22 at 100 days of net cash cycle days, and our goal is to finish fiscal ‘23 down five to 10 days from that. So, even though Q2 is forecasted to be higher, we expect reductions in the back half of this year. It'll come mainly from inventory reductions. I think inventory could come down 10 to 15 days from where we ended fiscal ‘22. But it's important to keep in mind, some of that inventory we’re liquidating, there's cash deposits associated with that inventory, that those deposits will be returned. So, again, net-net, I think we can reduce our cash cycle five to 10 days from the fiscal ‘22 level of 100 days. By doing that, we'll see free cash flow generation in the second half of the year and approaching that $50 million of free cash flow. The last thing I'd say is, Oliver is working with our regions and the supply chain teams on a number of initiatives, which he can touch on, but it revolves around aged inventory, demand signals from customers, and obviously trying to secure those golden screws from our suppliers. So, there can be a lot of variability with mix and demand that could change our projections, but that's what we're forecasting at this point. Oliver, anything you want to add?

Yes, I’ll add one thing there just to note that I think we previously talked about our variable incentive compensation program, and that has a 20% component that is aligned to essentially a management objective. And so, for that population of individuals, a significant portion of that population, either a significant piece of, or all of that 20%, has been aligned to inventory reduction targets through the fiscal year.

Okay, great. Very helpful. Thank you.

Our next question comes from Paul Chung with JPMorgan. Your line is now open.

Hi. Thanks for taking my question. So, just on Warehouse and factory automation, can you speak to kind specific products you're seeing demand strength? How's the firm positioned kind of versus competitors in the market? And are you seeing any pauses in demand from - after strong investments by end customers over the past couple of years?

This is Steve. I'll take that one. I wouldn't say we're seeing any significant changes, positive or negative, with the ramp of the factory automation products. Obviously, we see a few ebbs and flows with specific customers as they get new orders and do new installs. And so, I guess from my perspective, we have several programs we talked about ramping. They continue to ramp, and we always anticipated and knew that some of these would be a bit bumpy as they get orders for new installs. So, I wouldn't say there's any specific trend that I could highlight, positive or negative, with that area.

Okay, thanks for that. And then just on guidance for ’23, you mentioned sequential growth in the back half. You've seen somewhat of a wide range of sequential growth into fiscal third quarter in the past. You're also now facing some difficult year-on-year cost, but can you help us frame the pace of growth into the third quarter and given the visibility you have today? Thank you.

Sure. Thanks, Paul. This is Todd. I’ll take that one. I think it’s best to maybe start out with the fact that our markets, exclusive of SemiCap, are strong right now. I mean, they're solid and they're very good. Healthcare, Aerospace in particular are exceptionally strong. So, when we think about our outlook for the back half, it’s not much different than it was 90 days ago. It looks pretty similar to what it did 90 days ago. We have a little bit of a blip in Q2 because of the situation with SemiCap dropping rapidly, and also the new program ramps that we're working through right now. But we work through those and then the back half looks a lot like it did before ex the impact that we're expecting from SemiCap, which again, could be a couple of percent. So, when we think about sequential growth in the back half, I would say $40 million to $50 million per quarter, give or take, is what we're thinking as we look at Q3 and Q4. So, we expect it to be meaningful. And when we add that level of revenue, that puts us in really good position to achieve our 5.5% operating margin goal as we exit the fiscal year.

Oh, that's super helpful. And then for the 5.5%, is that the pace or is that for the full year, just to be clear?

I would call it exiting the year at this point. So, it'd be a good goal for us for Q4. I think Q3 might be a bit aggressive. Possible …

Great. Thank you. Very helpful.

[Operator instructions]. Our next question comes from Anja Soderstrom with Sidoti. Your line is now open.

Thank you for taking my questions. So, I'm just curious, where are you in the commercial air recovery?

Yes. I would say it's in the early stages. The demand for commercial aerospace is quite strong, but the supply has not caught up to the demand yet. So - and I’d kind of equate it to where we were at with elective healthcare or SemiCap 12 to 18 months ago.

Okay, thank you. And in terms of EMEA and new program wins there, it looked very strong in the presentation. Can you just elaborate on which regions within EMEA that you see strength in?

Yes, this is Steve. I can touch on this. So, we've got a couple of facilities over there, obviously. One is in Scotland one is in Oradea, Romania. Our facility in Romania is the one that's benefiting the most from these wins. As I highlighted, three of the wins of the five that I highlighted were headed for Oradea. So, the team over there has just been doing an exceptional job. And quite frankly, a lot of these wins are being rewards for the execution that we had through the pandemic. So, the Oradea facility is projected for significant growth as we go through the next few quarters.

Okay. Thank you. That was all from me.

I'm showing no further questions in queue at this time. I'd like to turn the call back to Todd Kelsey for closing remarks.

All right. Well, thank you, Liz. Again, I'd like to thank everybody who joined our call today. We appreciate your support and interest in Plexus. In closing, I'd like to reiterate that we remain quite bullish in regards to fiscal 2023. Thank you. Have a nice day.